Buspirone
Buspar · Bucapsol
Azapirone (5-HT1A Partial Agonist)Generic availableTDM data
Clinical Pharmacology The mechanism of action of buspirone is unknown. Buspirone differs from typical benzodiazepine anxiolytics in that it does not exert anticonvulsant or muscle relaxant effects. It also lacks the prominent sedative effect that is associated with more typical anxiolytics. In vitro preclinical studies have shown that buspirone has a high affinity for serotonin (5-HT1A) receptors. Buspirone has no significant affinity for benzodiazepine receptors and does not affect GABA binding in vitro or in vivo. Buspirone has moderate affinity for brain D2-dopamine receptors.
Compare Buspirone →FDA-Approved Indications
- Generalized anxiety disorder — short-term relief (adults)
Common Off-Label Uses
- MDD augmentation
- Social anxiety disorder
- PTSD
- SSRI-induced sexual dysfunction
- Behavioral disturbance in dementia
What Sets This Drug Apart
- 5-HT1A partial agonist with unique pharmacology: no GABA activity, no benzodiazepine cross-reactivity, no dependence or withdrawal potential
- FDA-approved for GAD only; effective augmentation strategy for SSRI-refractory anxiety (guideline-recommended combination)
- Onset of action 2-4 weeks — cannot be used as-needed for acute anxiety (unlike benzodiazepines)
- CYP3A4 substrate; grapefruit juice increases levels; avoid with strong CYP3A4 inhibitors
- No sedation, cognitive impairment, or psychomotor slowing — unlike benzodiazepines; safe in elderly and substance use populations